© 2002 European Society of Cardiology
Heart failure as an inflammatory condition: potential role for androgens as immune modulators
a Department of Cardiology, Royal Hallamshire Hospital Glossop Road, Sheffield S10 2JF, UK
b Academic Unit of Endocrinology, Division of Genomic Medicine, University of Sheffield Medical School Sheffield, UK
* Corresponding author. Tel.: +44-114-271-3473; fax: +44-114-271-2042. E-mail address: kevin.channer{at}sth.nhs.uk
 |
Abstract |
|---|
Heart failure has traditionally been considered a disease of the myocardium, with symptoms arising from altered haemodynamics. However, it is now recognised that, in addition to marked neuroendocrine disturbance, there is perturbation of cytokine expression in patients with heart failure, resulting in an inflammatory imbalance. This not only influences symptoms, but also plays a central role in the underlying pathophysiological processes of heart failure, leading to disease progression and poorer prognosis. Recognition of the influence of cytokines, in particular tumour necrosis factor, has opened a new avenue for potential therapies for heart failure. Current approaches involve immunomodulation, aimed at suppressing tumour necrosis factor. We suggest that androgens may potentially offer a superior therapeutic strategy by their well-recognised non-specific immunosuppressive and anti-inflammatory effects. Studies of cell lines, human mononuclear cells and animals in vivo have demonstrated the ‘anti-cytokine’ actions of androgens, and we have found a similar action in whole blood from patients with heart failure. These effects, along with the anabolic action of these agents, make androgens an attractive potential option for treatment of patients with heart failure.
Key Words: Androgens • Cytokines • Heart failure • Immunosuppression
Received December 17, 2001; Revised February 22, 2002; Accepted March 26, 2002
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. E. Fildes, S. M. Shaw, N. Yonan, and S. G. Williams The Immune System and Chronic Heart Failure: Is the Heart in Control? J. Am. Coll. Cardiol., March 24, 2009; 53(12): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Deschepper and B. Llamas Hypertensive Cardiac Remodeling in Males and Females: From the Bench to the Bedside Hypertension, March 1, 2007; 49(3): 401 - 407. [Full Text] [PDF]
|
|
|
|
 |
|
 J George, S Patal, D Wexler, Y Sharabi, E Peleg, Y Kamari, E Grossman, D Sheps, G Keren, and A Roth Circulating adiponectin concentrations in patients with congestive heart failure Heart, October 1, 2006; 92(10): 1420 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J Pugh, R D Jones, J N West, T H Jones, and K S Channer Testosterone treatment for men with chronic heart failure Heart, April 1, 2004; 90(4): 446 - 447. [Full Text] [PDF]
|
|